www.dailypolitical.com ·
John Kozarich Sells 459 Shares of Ligand Pharmaceuticals Nasdaqlgnd Stock
Topic context
Related topics
The full article is on the original publisher site.
AI insight
AI-generatedLigand Pharmaceuticals stock is expected to remain flat in the short and mid-term due to a small insider sale and an earnings miss already priced in. Key risk: if further insider sales occur, negative sentiment could increase.
Insider sale of 459 shares by a director, combined with an earnings miss, signals potential negative sentiment. However, the sale is small relative to holdings (1.09% decrease). No direct commercial mechanism beyond equity price impact; no supply chain or product-level effect.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Director John Kozarich sold 459 shares at $224.00 on May 12, 2026.
- Ligand Pharmaceuticals reported Q1 2026 EPS of $1.63, missing estimates by $0.21.
- Revenue was $51.72 million.
- Stock opened at $213.21, down 2.6%.
- Market cap is $4.27 billion.
Affected products & commodities
- (not specified)
Supply-chain signals
- (not specified)
Historical parallels
- Insider sales after earnings misses often lead to short-term stock weakness, but magnitude varies.
This analysis would be wrong if
if a significant insider sale or negative earnings report is released.
Related stories
thehindubusinessline.com
Sensex Nifty50 Today Stock Market Highlights 9th June 2026
proactiveinvestors.com
Ftse 100 Live London Blue Chips in the Red Gsk Deal Too Big for Some
benzinga.com
Taiwan Semiconductor Becomes Worlds Ninth Most Valuable Company
businesstoday.in
Spacex IPO Dividend Policy of Elon Musks Space Giant Explained Ahead of Historic Nasdaq Debut 535794 2026 06 09
dynamicbusiness.com